Pegloticase, Recombinant Uricase

Specification

• Cat#: THP-0105
• Product Name: Pegloticase, Recombinant Uricase
• Cas No: 885051-90-1
• Description: The product is a recombinant procine-like uricase. Similarly to rasburicase, pegloticase metabolises the conversion of uric acid to allantoin. This reduces the risk of precipitate formation and development of gout, since allantoin is five to ten times more soluble than uric acid. Pegloticase is a pegylated form of uricase which offers an extended half-life of ten-12 days compared to rasburicase's 8 hours. It also offers reduced immunogenicity due to the bulky PEG group. The longer haf-life allows for less frequent dosing at once every 2-4 weeks making pegloticase more convenient for chronic use.
• Sequences: TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL
• Molecular Weight: 34192.8533 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C1549H2430N408O448S8
• Endotoxin: <0.001 EU per 1 μg by the LAL method
• Application: For the treatment of chronic gout in adult patients refractory to conventional therapy.
• Concentration: 8 mg/ml

Pharmaceutical Information

• Pharmaceutical Application: Pegloticase
• Targets: Target 1. Uric acid